by Brenda Baletti, Ph.D., Childrens Health Defense:

Two new reports raise concerns about the dangers of Beyfortus, an immunization against RSV for infants that the Centers for Disease Control and Prevention added last year to the Childhood Immunization Schedule.

Infants treated for RSV with the monoclonal antibody nirsevimab have significantly higher mortality rates than those treated with a different monoclonal antibody or with a placebo, according to an analysis by the Japanese journal Med Check of three major randomized control trials.